This article is free to access.
Diabetic kidney disease is the leading cause of end-stage renal disease in developed and developing countries. Microalbuminuria is the gold standard for detection and prediction of diabetic kidney disease and cardiovascular risk disease in clinical practice. However, microalbuminuria has several limitations, such as lower sensitive, larger variability. It is urgent to explore higher sensitivity and specificity for earlier detection of diabetic kidney disease and more accurate prediction of the progression to end stage renal disease. We reviewed some new and important urinary biomarkers, such as: transferrin, immunoglobulin G, immunoglobulin M, Cystanic C, podocytes, type IV collagen, 8-oxo-7, 8-dihydro-2'-deoxyguanosine, ceruloplasmin, monocyte chemoattractant protein-1 and so on. We need good quality, long-term, large longitudinal trials to validate published biomarkers and find new biomarkers, considering biomarkers reviewed here are from small cross-sectional studies. © 2013 cheng et al.; licensee BioMed Central Ltd.
Wang, C., Li, C. C., Gong, W. Y., & Lou, T. (2013, February 4). New urinary biomarkers for diabetic kidney disease. Biomarker Research. BioMed Central Ltd. https://doi.org/10.1186/2050-7771-1-9
Mendeley helps you to discover research relevant for your work.